These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17990317)

  • 41. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients.
    Ming Z; Jiang D; Hu Q; Li X; Huang J; Xu Y; Liu Y; Xu C; Hua X; Hou Y
    Diagn Pathol; 2014 Aug; 9():153. PubMed ID: 25106743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
    Hou J; Jiang D; Zhang J; Gavine PR; Xu S; Liu Y; Xu C; Huang J; Tan Y; Wang H; Lu Y; Zheng L; Hou Y; Tan L
    Hum Pathol; 2014 Feb; 45(2):352-8. PubMed ID: 24360885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.
    Vorkas PA; Poumpouridou N; Agelaki S; Kroupis C; Georgoulias V; Lianidou ES
    J Mol Diagn; 2010 Sep; 12(5):697-704. PubMed ID: 20616362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PIK3CA mutation enrichment and quantitation from blood and tissue.
    Keraite I; Alvarez-Garcia V; Garcia-Murillas I; Beaney M; Turner NC; Bartos C; Oikonomidou O; Kersaudy-Kerhoas M; Leslie NR
    Sci Rep; 2020 Oct; 10(1):17082. PubMed ID: 33051521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncogenic PIK3CA mutations in lobular breast cancer progression.
    Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
    Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
    Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
    J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highly Sensitive Detection of PIK3CA Mutations by Looping-Out Probes-Based Melting Curve Analysis.
    Xu B; Lan Y; Luo D; Zheng Y; Ni R; Su G; Huang Q; Li Q
    Biochem Genet; 2024 Feb; 62(1):77-94. PubMed ID: 37249716
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
    Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
    Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
    Barbi S; Cataldo I; De Manzoni G; Bersani S; Lamba S; Mattuzzi S; Bardelli A; Scarpa A
    J Exp Clin Cancer Res; 2010 Apr; 29(1):32. PubMed ID: 20398348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
    Alvarez-Garcia V; Bartos C; Keraite I; Trivedi U; Brennan PM; Kersaudy-Kerhoas M; Gharbi K; Oikonomidou O; Leslie NR
    Sci Rep; 2018 Mar; 8(1):4290. PubMed ID: 29523855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis.
    Helmijr J; Motta G; Jongbloed L; de Weerd V; van Bergen L; Verschoor N; Stella S; Beaufort C; Vigneri P; Martens JWM; Wilting SM; Jansen MPHM
    J Appl Lab Med; 2024 Sep; 9(5):913-925. PubMed ID: 39012846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A PIK3CA pyrosequencing-based assay that excludes pseudogene interference.
    Baker CL; Vaughn CP; Samowitz WS
    J Mol Diagn; 2012 Jan; 14(1):56-60. PubMed ID: 22026957
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
    J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of PIK3CA mutations in breast cancer subtypes.
    Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
    Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.